Torasawa M, Yoshida T, Yagishita S, Shimoda Y, et al. Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis. Lung Cancer 2022;167:49-57.
PMID: 35397298